Form 4: Brainstorm Cell Therapeutics Co-CEO Stacy Lindborg Reports Acquisition of Shares Through Restricted Stock Awards

Stacy Lindborg, Co-Chief Executive Officer of Brainstorm Cell Therapeutics, reports acquiring 241,935 shares of common stock through restricted stock awards.

Summary

• On March 11, 2024, Stacy Lindborg, Co-Chief Executive Officer of Brainstorm Cell Therapeutics Inc., acquired 241,935 shares of common stock.
• These shares were obtained through restricted stock awards (RSAs) as part of the Issuer's grant of equity awards in the ordinary course.
• The RSAs will vest in equal yearly installments over two years, with vesting occurring on the first and second anniversary of the grant date.

Sentiment

Score: 6

Explanation: The sentiment is neutral as it reports a standard equity grant. It's neither overwhelmingly positive nor negative.

Positives

• The grant of restricted stock awards to the Co-CEO aligns her interests with those of the shareholders.
• The vesting schedule of two years encourages long-term commitment from the Co-CEO.

Industry Context

This type of equity compensation is common in the biotechnology industry to attract and retain key executives.

Comparison to Industry Standards

• Equity grants are a standard component of executive compensation packages in the biotech industry.
• Companies like Amgen, Biogen, and Gilead Sciences routinely use stock options and restricted stock units to incentivize their leadership teams.
• The vesting schedule of two years is relatively short compared to some companies that use three or four-year vesting periods.

Stakeholder Impact

• The equity grant aligns the Co-CEO's interests with those of the shareholders, potentially leading to increased shareholder value.
• Employees may view the equity grant as a positive sign of the company's commitment to its leadership.

Key Dates

Keywords

Brainstorm Cell Therapeutics, Stacy Lindborg, restricted stock awards, equity awards, Form 4, BCLI, Co-Chief Executive Officer